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Pain  is  the  most  unbearable  symptom  accompanying  primary  bone  cancers  and  bone
metastases. Bone resorptive disorders are often associated with hypercalcemia, contributing to
the pathologic process. Nitrogen-containing bisphosphonates (NBPs) are efficiently used to treat
bone cancers and metastases. Apart from their toxic effect on cancer cells, NBPs also provide
analgesia via poorly understood mechanisms. We previously showed that NBPs, by inhibiting the
mevalonate pathway, induced formation of novel ATP analogs such as ApppI [1-adenosin-5'-yl
ester 3-(3-methylbut-3-enyl) triphosphoric acid diester], which can potentially be involved in
NBP analgesia. In this study, we used the patch-clamp technique to explore the action of ApppI
on native ATP-gated P2X receptors in rat sensory neurons and rat and human P2X3, P2X2, and
P2X7 receptors expressed in human embryonic kidney cells. We found that although ApppI has
weak agonist activity, it is a potent inhibitor of P2X3 receptors operating in the nanomolar
range. The inhibitory action of ApppI was completely blocked in hypercalcemia-like conditions
and was stronger in human than in rat P2X3 receptors. In contrast, P2X2 and P2X7 receptors
were insensitive to ApppI, suggesting a high selectivity of ApppI for the P2X3 receptor subtype.
NBP, metabolite isopentenyl pyrophosphate, and endogenous AMP did not exert any inhibitory
action, indicating that only intact ApppI has inhibitory activity. Ca2+-dependent inhibition was
stronger in trigeminal neurons preferentially expressing desensitizing P2X3 subunits than in
nodose ganglia neurons, which also express nondesensitizing P2X2 subunits. Altogether, we
characterized  previously  unknown  purinergic  mechanisms  of  NBP-induced  metabolites  and
suggest ApppI as the endogenous pain inhibitor contributing to cancer treatment with NBPs.
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